Drug Trial Radar · NCT07363460
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Nov 18, 2025
Primary completion
Nov 5, 2027
Study completion Jul 6, 2028
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus placebo in Patients With Lupus Nephritis
Conditions
- Lupus Nephritis (LN)
Interventions
HSK39297 200mgQDDrug
once daily, oral administration of HSK39297 tablets 200mg from Day 1 to Week 52.
HSK39297 300mgQDDrug
once daily, oral administration of HSK39297 tablets 300mg from Day 1 to Week 52.
PlaceboDrug
once daily, oral administration of placebo from Day 1 to Week 52.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of 24h-UPCR compared to BaselineTime frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.